# BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma

> **NCT06793449** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 80 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** anti-BCMA CAR-T
- **BIOLOGICAL:** ASCT

## Key facts

- **NCT ID:** NCT06793449
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-05
- **Primary completion:** 2026-12
- **Final completion:** 2030-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06793449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06793449, "BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06793449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*